Kalshi opens $100K betting market for drug trials and FDA decisions

Prediction markets have entered the biopharma industry, letting traders wager on clinical trial outcomes and FDA approval decisions for the first time.

Kalshi, one of the largest regulated U.S. prediction market exchanges, on Thursday launched betting contracts tied to pharmaceutical clinical trials and drug approval decisions, accepting more than $100,000 in wagers within hours of going live. The markets, developed in partnership with data firm AppliedXL, allow trading on whether late-stage trials will meet their primary endpoints and whether the Food and Drug Administration will grant full approval to specific drugs.

"The main purpose of the trial is information-seeking. We are trying to find truth, and we're trying to advance medicine," said Nicholas Zaorsky, a professor of radiation oncology at the Mayo Clinic who has been involved in numerous clinical trials. "Once you start to introduce all these other incentives, that main objective goes out the window."

The initial slate of contracts covers more than a dozen outcomes, focused on Phase 3 trials run by companies with market capitalizations exceeding $500 million. Traders can bet on whether Gilead Sciences will win FDA approval for its experimental cancer drug anito-cel by year-end, whether AriBio's Alzheimer's drug will meet its trial goals, and when Eli Lilly's weight-loss drug retatrutide will receive regulatory clearance. One contract asks whether the FDA will approve a cure for Type 1 diabetes before 2033 — 56% of bettors say no.

Kalshi argues the markets will surface pharmaceutical information that typically remains opaque, translating expert knowledge into a single public probability. The company has implemented employment verification and pledged to bar trading by anyone with insider knowledge, including company employees, lead investigators, biostatisticians, and safety-monitoring committee members. Trial participants are also prohibited from trading. But researchers and bioethicists warn that financial incentives could corrupt the clinical trial process itself.

Insider Trading and Trial Integrity Risks

Even with Kalshi's guardrails, critics say the risk of manipulation remains significant. Insider trading in prediction markets is typically detected retroactively, meaning a trial could be compromised before regulators intervene, Zaorsky said. People with privileged access to unblinded data — including doctors and nurses who observe patient subsets — could place profitable bets before results are publicly disclosed.

Jonathan Kimmelman, a bioethicist at McGill University who consulted with Kalshi on the market criteria, said the very premise of predicting trial outcomes may be flawed. Research is inherently unpredictable, he noted, and if prediction markets produce strong signals, it may indicate a research environment where outcomes are already known rather than genuinely exploratory. He also warned that the markets could drive conformity, reinforcing investment in well-known drug targets while starving lesser-known areas that don't trade well.

"Any kind of adulteration that happens in the clinical trial process is ultimately threatening the well-being of people who are using that drug and the evidence about it," Kimmelman said.

Kalshi and AppliedXL acknowledged a paradox in their approach: the same criteria that make markets trustworthy — late-stage trials, large companies, clear endpoints — bias the exchange toward programs that are already well-funded, away from the high-uncertainty research that most needs external signal. The company said it aims to expand into earlier-stage trials and smaller companies if the initial markets operate smoothly.

What's at Stake for Biopharma and Regulators

The launch opens a new frontier for prediction markets, which have already expanded into sports, politics, and reality television. For investors, the contracts offer a more direct way to bet on specific drug development events than is possible in equity markets, particularly for large pharmaceutical companies running multiple trials simultaneously. For drugmakers, Kalshi argues the markets provide an incentive-aligned external estimate that could sharpen capital-allocation decisions.

But the financial incentives could also influence patient behavior, with trial participants potentially choosing to withdraw or stay enrolled based on betting odds rather than medical advice, researchers said. The U.S. Commodity Futures Trading Commission, which oversees Kalshi, has already blocked the exchange from canceling certain trades in other markets despite a court order, signaling potential regulatory friction ahead.

Anne Wojcicki, CEO of the 23andMe Research Institute, who has discussed the topic with Kalshi, acknowledged the ethical questions but said prediction markets can ultimately help patients follow trials relevant to their disease. "It's very patient-empowering," she said.

This article is for informational purposes only and does not constitute investment advice.